PT3541387T - Dose e regime para inibidores de interação de hdm2-p53 - Google Patents
Dose e regime para inibidores de interação de hdm2-p53Info
- Publication number
- PT3541387T PT3541387T PT178043048T PT17804304T PT3541387T PT 3541387 T PT3541387 T PT 3541387T PT 178043048 T PT178043048 T PT 178043048T PT 17804304 T PT17804304 T PT 17804304T PT 3541387 T PT3541387 T PT 3541387T
- Authority
- PT
- Portugal
- Prior art keywords
- hdm2
- regimen
- dose
- interaction inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662422144P | 2016-11-15 | 2016-11-15 | |
| US201762479391P | 2017-03-31 | 2017-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3541387T true PT3541387T (pt) | 2021-07-14 |
Family
ID=60452703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT178043048T PT3541387T (pt) | 2016-11-15 | 2017-11-14 | Dose e regime para inibidores de interação de hdm2-p53 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10966978B2 (pt) |
| EP (1) | EP3541387B1 (pt) |
| JP (1) | JP6890659B2 (pt) |
| KR (1) | KR102325778B1 (pt) |
| CN (2) | CN115252786A (pt) |
| AU (1) | AU2017362040C1 (pt) |
| CA (1) | CA3043004A1 (pt) |
| DK (1) | DK3541387T3 (pt) |
| ES (1) | ES2880149T3 (pt) |
| HU (1) | HUE055509T2 (pt) |
| IL (1) | IL266171B (pt) |
| MX (1) | MX2019005623A (pt) |
| PL (1) | PL3541387T3 (pt) |
| PT (1) | PT3541387T (pt) |
| RU (1) | RU2762573C2 (pt) |
| SI (1) | SI3541387T1 (pt) |
| TW (1) | TWI757367B (pt) |
| WO (1) | WO2018092020A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| CA3043004A1 (en) | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
| KR20190129889A (ko) * | 2017-03-31 | 2019-11-20 | 노파르티스 아게 | 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법 |
| US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN110963958A (zh) * | 2018-09-30 | 2020-04-07 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| CA3115716A1 (en) * | 2018-10-30 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | Method of treatment of p53 wt tumors |
| AU2019400978A1 (en) | 2018-12-20 | 2021-06-24 | Novartis Ag | Extended low dose regimens for MDM2 inhibitors |
| KR20210038366A (ko) * | 2019-09-30 | 2021-04-07 | 한미약품 주식회사 | Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| US20230270721A1 (en) * | 2020-04-16 | 2023-08-31 | Albert Einstein College Of Medicine | Inhibition of bax-mediated cell death by eltrombopag |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
| US20030139373A1 (en) | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| EA201390682A1 (ru) | 2010-11-12 | 2014-01-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Спирооксиндольные антагонисты mdm2 |
| US9062071B2 (en) * | 2011-12-21 | 2015-06-23 | Merck Sharp & Dohme Corp. | Substituted piperidines as HDM2 inhibitors |
| UY34591A (es) * | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| ES2785203T3 (es) | 2013-12-05 | 2020-10-06 | Hoffmann La Roche | Tratamiento de combinación novedoso para leucemia mielógena aguda (LMA) |
| TW201613576A (en) * | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| WO2016100882A1 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| CA2981753A1 (en) | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| RU2018108804A (ru) | 2015-08-14 | 2019-09-16 | Новартис Аг | Фармацевтические комбинации и их применение |
| CA3043004A1 (en) | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
| KR20190129889A (ko) * | 2017-03-31 | 2019-11-20 | 노파르티스 아게 | 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법 |
-
2017
- 2017-11-14 CA CA3043004A patent/CA3043004A1/en active Pending
- 2017-11-14 PT PT178043048T patent/PT3541387T/pt unknown
- 2017-11-14 HU HUE17804304A patent/HUE055509T2/hu unknown
- 2017-11-14 JP JP2019525886A patent/JP6890659B2/ja active Active
- 2017-11-14 RU RU2019118261A patent/RU2762573C2/ru active
- 2017-11-14 PL PL17804304T patent/PL3541387T3/pl unknown
- 2017-11-14 CN CN202210905351.1A patent/CN115252786A/zh active Pending
- 2017-11-14 AU AU2017362040A patent/AU2017362040C1/en active Active
- 2017-11-14 EP EP17804304.8A patent/EP3541387B1/en active Active
- 2017-11-14 KR KR1020197016797A patent/KR102325778B1/ko active IP Right Grant
- 2017-11-14 WO PCT/IB2017/057097 patent/WO2018092020A1/en unknown
- 2017-11-14 MX MX2019005623A patent/MX2019005623A/es unknown
- 2017-11-14 SI SI201730843T patent/SI3541387T1/sl unknown
- 2017-11-14 DK DK17804304.8T patent/DK3541387T3/da active
- 2017-11-14 US US16/461,005 patent/US10966978B2/en active Active
- 2017-11-14 CN CN201780070276.9A patent/CN109982702A/zh active Pending
- 2017-11-14 ES ES17804304T patent/ES2880149T3/es active Active
- 2017-11-15 TW TW106139404A patent/TWI757367B/zh active
-
2019
- 2019-04-22 IL IL266171A patent/IL266171B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE055509T2 (hu) | 2021-12-28 |
| US10966978B2 (en) | 2021-04-06 |
| RU2762573C2 (ru) | 2021-12-21 |
| PL3541387T3 (pl) | 2021-10-25 |
| CN115252786A (zh) | 2022-11-01 |
| KR20190084292A (ko) | 2019-07-16 |
| WO2018092020A1 (en) | 2018-05-24 |
| EP3541387B1 (en) | 2021-04-21 |
| RU2019118261A3 (pt) | 2021-03-18 |
| IL266171B (en) | 2021-12-01 |
| TWI757367B (zh) | 2022-03-11 |
| KR102325778B1 (ko) | 2021-11-12 |
| IL266171A (en) | 2019-06-30 |
| TW201822817A (zh) | 2018-07-01 |
| US20190298719A1 (en) | 2019-10-03 |
| AU2017362040A1 (en) | 2019-05-02 |
| JP6890659B2 (ja) | 2021-06-18 |
| SI3541387T1 (sl) | 2021-08-31 |
| RU2019118261A (ru) | 2020-12-17 |
| AU2017362040C1 (en) | 2020-09-10 |
| CN109982702A (zh) | 2019-07-05 |
| ES2880149T3 (es) | 2021-11-23 |
| CA3043004A1 (en) | 2018-05-24 |
| DK3541387T3 (da) | 2021-07-19 |
| JP2020500190A (ja) | 2020-01-09 |
| AU2017362040B2 (en) | 2020-04-30 |
| MX2019005623A (es) | 2019-08-14 |
| EP3541387A1 (en) | 2019-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269462A (en) | MDM2 inhibitors and therapeutic methods that use them | |
| HK1243326A1 (zh) | 溴結構域抑制劑 | |
| IL266171A (en) | Dosage and therapeutic regimen for hdm2-p53 interaction inhibitors | |
| ME03759B (me) | Inhibitori bromodomena | |
| ZA201801747B (en) | Medication packaging and dose regimen system | |
| HK1243072A1 (zh) | 布羅莫結構域抑制劑及其用途 | |
| HK1243415A1 (zh) | 溴結構域抑制劑 | |
| ZA201705591B (en) | Medication packaging and dose regimen system | |
| GB201713653D0 (en) | Dosage regimen | |
| HK1245153A1 (zh) | Btk抑制劑組合和給藥方案 | |
| IL268993A (en) | Dosage and therapeutic regimen for hdm2-p53 interaction inhibitors in hematologic tumors | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| GB201521217D0 (en) | Dosage regimens | |
| IL247083B (en) | dose fgh–18 | |
| GB201418710D0 (en) | Dosage regimen | |
| PL3250089T3 (pl) | Urządzenie do wielokrotnego dozowania i magazynek | |
| IL266255A (en) | New dosage regimen | |
| GB2544278B (en) | Syringes and inserts for syringes | |
| HK1216970A2 (zh) | 種行李箱包角裝置及行李箱 | |
| ZA201807614B (en) | Bromodomain inhibitors | |
| GB201617850D0 (en) | Dosage regimen | |
| GB201610502D0 (en) | Dosage regimen | |
| GB201521216D0 (en) | Dosage regimen | |
| GB201418708D0 (en) | Dosage regimen | |
| GB201411345D0 (en) | Nicotine dosage regimen |